A Phase II, Randomized, Double-blind, Safety and Immunogenicity Trial of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Elderly Adults
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs TAK 214 (Primary)
- Indications Norovirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Takeda
- 06 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2017.
- 06 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 29 Aug 2016 Planned End Date changed from 1 Apr 2017 to 1 Sep 2017.